Delivery Order SPE2DB22D2206-SPE2DB25FGV95
Award Date 5/5/25
Potential Completion Date 5/27/25
Potential Value $3.5K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a delivery order valued at $6,709.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial on December 10, 2025, with completion targeted for January 2, 2026. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office division located in Conshohocken, Pennsylvania. The product is a rabies immunoglobulin (human) preparation used for post-exposure prophylaxis in...
- The Defense Logistics Agency awarded a delivery order valued at $5,367.52 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial on November 14, 2025, with an ultimate completion date of December 8, 2025. This firm fixed price delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,934.96 for HYPERRAB 300 Unit/ML Vial 5ML on October 30, 2025, with completion expected by November 21, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for post-exposure prophylaxis in rabies prevention, supporting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract operates under a firm fixed-price structure and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $3,467.48 to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. The order, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,732.55 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with a completion date of September 18, 2025. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December...
- The Defense Logistics Agency awarded a $8,954.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, with an ultimate completion date of October 7, 2025. This non-set-aside competitive award was issued on September 16, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for post-exposure rabies prophylaxis in military and federal healthcare...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,616.74 on June 18, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 3mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 11, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The contract represents a non-set-aside award, reflecting the contractor's...
- On September 3, 2025, the Defense Logistics Agency awarded a delivery order valued at $4,851.14 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for...